Mednet Logo
Community

Would you use the MIPSS-PV risk scoring to decide in decision making for cytoreductive therapy in PV?

If so, would you do bone marrow biopsy or send for NGS panel in blood to look for high risk mutations? NCCN lists this as the risk criteria.
1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Taussig Cancer Institute
Answered on

I think the MIPSS-PV is helpful in understanding predicted overall survival and appreciating the risk of progression, the decision to cytoreduce is still routed in the classic thrombosis risk model of age plus thrombosis history.

I would certainly recommend getting an NGS panel to better understand ...

Join for free or sign in to see the full answer